Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

Core Insights - Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for inflammation-mediated cardiovascular and neurodegenerative diseases [3][4] - The company will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2025 [1][2] Company Overview - Ventyx specializes in oral small molecule therapeutics targeting conditions with high unmet medical needs, leveraging expertise in medicinal chemistry, structural biology, and immunology [3] - The company has a portfolio of NLRP3 inhibitors, including VTX2735 for recurrent pericarditis and VTX3232 for obesity-related cardiovascular risks and Parkinson's disease [4] Upcoming Events - The fireside chat at the Jefferies Global Healthcare Conference is scheduled for November 19, 2025, from 11:00 to 11:25 AM GMT, with a webcast available on the company's website [2]